Crossmark

Efficacy and safety of vunakizumab between super responders and non-super responders of patients with moderate-to-severe plaque psoriasis: a post-hoc exploratory analysis of a phase III trial

Crossref DOI link: https://doi.org/10.1007/s00210-025-04911-4

Published Online: 2026-01-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Liu, Ougen

Kou, Caixia

Yu, Simin

Hu, Huizhong

Chen, Xiaoxiao

Jiang, Meiying

Ren, Shifeng
Funding

Funding for this research was provided by:

the Health Commission of Jiangxi Province of China (20203335)

National Natural Science Foundation of China (82060574)
License Information

Text and Data Mining valid from 2026-01-02

Version of Record valid from 2026-01-02
More Information

Article History

Received: 30 October 2025

Accepted: 9 December 2025

First Online: 2 January 2026

Declarations

:

: This was a post-hoc exploratory analysis of a phase III trial, and the ethics approval number for the principal center (Huashan Hospital, Fudan University) was 20201231.

: Not applicable.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below